Table 1.
Baseline characteristics of all peg-IFN-treated CHB patients
| Characteristic | All | SR group | NSR group | P value |
|---|---|---|---|---|
| (N = 30) | (N = 9) | (N = 21) | (SR vs. NSR) | |
| Age, year (median) | 26.57 ± 4.17 | 27.00 ± 3.08 | 26.38 ± 4.62 | 0.216 |
| Gender (male/female) | 18/12 | 8/1 | 10/11 | 0.03 |
| HBV genotype (%) | 0.614 | |||
| B | 10 (33.3%) | 3 (33.3%) | 7 (33.3%) | |
| C | 20 (66.7%) | 6 (66.7%) | 14 (66.7%) | |
| ALT (U/L, median (range)) | 120 (66.8–174.0) | 131.0 (96.7–181.0) | 115.0 (59.0–174.0) | 0.380 |
| HBV DNA (log10 IU/mL) | 7.57 ± 1.10 | 7.52 ± 1.05 | 7.59 ± 1.15 | 0.878 |
| HBsAg (log10 IU/mL) | 3.78 ± 0.64 | 3.59 ± 0.49 | 3.86 ± 0.69 | 0.310 |
| HBcrAg (log10 KU/mL) | 5.41 ± 1.23 | 5.24 ± 1.45 | 5.48 ± 1.16 | 0.636 |
| HBV RNA (log10 copies/mL) | 7.73 ± 1.18 | 7.72 ± 1.42 | 7.75 ± 1.09 | 0.959 |
| HBV cccDNA (copies/cell, median (range)) | 33.8 (15.4–76.4) | 30.0 (13.2–100.8) | 34.4 (13.7–66.7) | 0.946 |